Day: October 20, 2025

Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC) No new safety or tolerability issues identified in pooled analysis of ongoing pivotal Phase 3 studyPHILADELPHIA and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces encouraging clinical biomarker data in its ongoing pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer. The findings are being presented in BriaCell’s poster presentation at the European Society for Medical Oncology...

NEWPORT BEACH, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company” or “we”), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its operating subsidiary AGA Precision Systems LLC (“AGA”) has reported a sales backlog of approximately over $711,000 in current orders logged into its Material Requirements Planning system, Sage100. AGA has also confirmed that it is actively bidding on additional Request for Quotations totaling over $700,000 from new customers. PMGC believes AGA’s current backlog and pending orders reflect robust demand, underscoring AGA’s growth momentum and the strong relationships it continues to build with both existing and new customers. PMGC also believes the backlog and pending orders strengthen...

Manhattan Showing with assay results returning uranium grades ranging from 0.72% to 8.10% U₃O₈ in outcrop grab samples. VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) — Aventis Energy Inc. (“Aventis” or the “Company”) (CSE:AVE | FRA:C0O0 | OTC: VBAMF) is pleased to announce final assay results from its 2025 exploration program at the Corvo Uranium Project (“Corvo”, or the “Project”), currently under a three-year earn-in option agreement with Standard Uranium Ltd. (“Standard”). From July 4 to July 16, 2025, the Company completed a detailed mapping and sampling program across historical uranium showings and zones of interest on the Project. Assay results confirm uranium mineralization across the Project, including high-grade* surface mineralization at the Manhattan Showing. Highlights:High-Grade Uranium at Surface:...

New AI Subscription Platform Integrates Edge Hardware, Cloud Intelligence and Vodafone IoT Connectivity to Unlock Recurring Revenue IRVINE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, and Vodafone IoT, a global leader in managed IoT connectivity services, today announced a partnership to help businesses optimize performance and unlock recurring revenue in energy-intensive industries. Available this fall in the United States and Canada, Kompress.ai by Lantronix is a turnkey, brand-agnostic AI-powered subscription platform designed to transform the $27 billion+ global industrial air compressor market by cutting costs, reducing downtime and enabling sustainability compliance. The platform combines Lantronix’s Edge hardware...

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX. The titles for the accepted abstracts are provided below and accessible online at: https://www.asn-online.org/education/kidneyweek/2025/program-search-abstract.aspx Late-Breaking Poster Presentation Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)Session Title: Late-Breaking Science Posters [LB-PO]Session Date, Time: November 6,...

TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) — Consolidated Lithium Metals Inc. (TSXV: CLM | FRA: Z36) (“CLM” or the “Company”) is pleased to announce that it will be hosting a corporate update presentation with analysts and investors via live webinar on Wednesday, October 22, 2025, at 4:30 p.m. (Toronto time). Participants can register to attend at the following web address: Registration link: https://us02web.zoom.us/meeting/register/97-DDgRsQ0qxA4CbpSCuhw Specifically, the webinar will feature CLM’s Chief Executive Officer, Richard Quesnel, to discuss updates on the Company’s business developments. About Consolidated Lithium Metals Inc. Consolidated Lithium Metals Inc. is a Canadian junior mining exploration company trading under the symbol “CLM” on the TSX Venture Exchange and “Z36” on the Frankfurt Stock Exchange. The Company is...

Vancouver, Canada, Oct. 20, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent application by the United States Patent and Trademark Office (USPTO) for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing binge behavior disorders. The patent application stems from Clearmind’s ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC). This therapy targets multiple binge behaviors, including excessive alcohol consumption binge eating, smoking, compulsive shopping, and problematic...

TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a U.S. patent application by the United States Patent and Trademark Office. The patent relates to an innovative combination therapy of MEAI (5-methoxy-2-aminoindane) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing binge behavior disorders. The patent refers to multiple binge behaviors, including excessive alcohol consumption, eating disorders, tobacco use, compulsive shopping, and problematic...

Atsinaujinančios Energetikos Investicijos invites investors to join the Investor webinar scheduled on the 21 October 2025 at 14:00 (in English) and 10:00 (in Lithuanian) (EEST/Baltic time). During the call UTIB UAB Atsinaujinančios energetikos investicijos (Issuer) Investment Company Manager Mantas Auruškevičius and Orion Securities (Issue organizer) Head of Investment Banking Mykantas Urba will present bond issue details and answer investor questions. 21 October 2025 at 14:00 (in English) Register here. 21 October 2025 at 10:00 (in Lithuanian) Register here. Key bond issue details:Issuer: UTIB UAB Atsinaujinančios energetikos investicijos Coupon rate: 8.5% Maturity: 13 months Coupon payment rate: semi-annual Total bond programme size: up to EUR 50m Size of the first series and tranche: up to EUR 25m Subscription period of the Bonds: 15-31...